JP2020502183A - アミノ酸組成物ならびに筋肉疾患および障害の治療方法 - Google Patents

アミノ酸組成物ならびに筋肉疾患および障害の治療方法 Download PDF

Info

Publication number
JP2020502183A
JP2020502183A JP2019532941A JP2019532941A JP2020502183A JP 2020502183 A JP2020502183 A JP 2020502183A JP 2019532941 A JP2019532941 A JP 2019532941A JP 2019532941 A JP2019532941 A JP 2019532941A JP 2020502183 A JP2020502183 A JP 2020502183A
Authority
JP
Japan
Prior art keywords
amino acid
acid entity
composition
entity
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019532941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502183A5 (cg-RX-API-DMAC7.html
Inventor
ハミル，マイケル
アフェヤン，ラフィー
コンブ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of JP2020502183A publication Critical patent/JP2020502183A/ja
Publication of JP2020502183A5 publication Critical patent/JP2020502183A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019532941A 2016-12-19 2017-12-19 アミノ酸組成物ならびに筋肉疾患および障害の治療方法 Pending JP2020502183A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US62/436,073 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US62/443,205 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US62/491,776 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US62/545,358 2017-08-14
US201762576321P 2017-10-24 2017-10-24
US62/576,321 2017-10-24
PCT/US2017/067368 WO2018118957A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders

Publications (2)

Publication Number Publication Date
JP2020502183A true JP2020502183A (ja) 2020-01-23
JP2020502183A5 JP2020502183A5 (cg-RX-API-DMAC7.html) 2021-02-12

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532941A Pending JP2020502183A (ja) 2016-12-19 2017-12-19 アミノ酸組成物ならびに筋肉疾患および障害の治療方法

Country Status (21)

Country Link
US (3) US20180207119A1 (cg-RX-API-DMAC7.html)
EP (1) EP3554493A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020502183A (cg-RX-API-DMAC7.html)
KR (1) KR20190099243A (cg-RX-API-DMAC7.html)
CN (1) CN110267655A (cg-RX-API-DMAC7.html)
AU (1) AU2017379825A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019012476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046558A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001685A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019006292A2 (cg-RX-API-DMAC7.html)
CU (1) CU20190057A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP19043725A (cg-RX-API-DMAC7.html)
IL (1) IL267210A (cg-RX-API-DMAC7.html)
JO (1) JOP20190147A1 (cg-RX-API-DMAC7.html)
MA (1) MA50763A (cg-RX-API-DMAC7.html)
MX (1) MX2019007352A (cg-RX-API-DMAC7.html)
PE (1) PE20191206A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501339A1 (cg-RX-API-DMAC7.html)
TW (1) TWI780096B (cg-RX-API-DMAC7.html)
WO (1) WO2018118957A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903581B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
AU2018318091A1 (en) * 2017-08-14 2020-02-13 Axcella Health Inc. Amino acid compositions for the treatment of neuronal injury
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
EP3810168A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Methods of manufacturing amino acid compositions
JP2021529736A (ja) * 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 炎症の軽減又は治療のための組成物及び方法
EP3856167A1 (en) * 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Use of histidine, glycine and other aminoacids for preventing insulin resistance and/or diabetes
US12317914B2 (en) 2019-06-07 2025-06-03 Societe Des Produits Nestle S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
KR102802853B1 (ko) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521256A (ja) * 2000-02-01 2003-07-15 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪筋量及び筋力を増強するためのαリポ酸含有食物補充物質
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008534599A (ja) * 2005-03-29 2008-08-28 味の素株式会社 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
EP2744356A4 (en) * 2011-08-19 2015-05-27 Musclepharm Corp COMPOSITIONS AND METHODS FOR INHIBITING INCOUNTERANCE IN ANIMALS
EP3060231A1 (en) * 2013-10-23 2016-08-31 The Whitehead Institute for Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521256A (ja) * 2000-02-01 2003-07-15 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪筋量及び筋力を増強するためのαリポ酸含有食物補充物質
JP2008534599A (ja) * 2005-03-29 2008-08-28 味の素株式会社 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions

Also Published As

Publication number Publication date
ZA201903581B (en) 2020-12-23
PE20191206A1 (es) 2019-09-10
IL267210A (en) 2019-08-29
CL2019001685A1 (es) 2019-08-30
US20180207119A1 (en) 2018-07-26
US20180169046A1 (en) 2018-06-21
US20180169047A1 (en) 2018-06-21
KR20190099243A (ko) 2019-08-26
EP3554493A1 (en) 2019-10-23
PH12019501339A1 (en) 2019-09-30
JOP20190147A1 (ar) 2019-06-18
CO2019006292A2 (es) 2019-06-28
WO2018118957A1 (en) 2018-06-28
ECSP19043725A (es) 2019-07-31
CA3046558A1 (en) 2018-06-28
BR112019012476A2 (pt) 2020-04-14
MX2019007352A (es) 2019-09-05
TWI780096B (zh) 2022-10-11
MA50763A (fr) 2019-10-23
CN110267655A (zh) 2019-09-20
TW201827068A (zh) 2018-08-01
CU20190057A7 (es) 2020-02-04
AU2017379825A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP2020502183A (ja) アミノ酸組成物ならびに筋肉疾患および障害の治療方法
US11571404B2 (en) Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10973793B2 (en) Compositions and methods for the treatment of fat infiltration in muscle
BR112020002244A2 (pt) aminoácidos de cadeia ramificada para o tratamento de lesão neurológica
WO2021178860A1 (en) Amino acid compositions and methods for muscle and myotube modulation
US20230044475A1 (en) Compositions and methods involving amino acids for the treatment of fat infiltrations in muscle
US20230105984A1 (en) Compositions and methods for the treatment of liver diseases and disorders
OA19826A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
OA20063A (en) Amino acid compositions for the treatment of liver disease.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230328